Secarna Pharmaceuticals

Secarna Pharmaceuticals is a private, pre-clinical stage biotech based in Martinsried, Germany, founded in 2005. The company's core asset is its AI-driven OligoCreator® platform, which integrates delivery technologies to rapidly identify and characterize novel oligonucleotide drug candidates. Secarna operates through a hybrid business model, advancing its own pipeline in oncology and immunology while actively partnering its platform with other biopharmaceutical companies. Recent strategic collaborations with entities like Curie.Bio and Protalix BioTherapeutics highlight its role as a technology enabler in the oligonucleotide space.

OligoCreator®: An AI-empowered drug discovery platform that integrates delivery technologies to rapidly identify and characterize best-in-class antisense oligonucleotide (ASO) and siRNA therapeutics.

Secarna competes with established oligonucleotide leaders like Ionis and Alnylam, as well as other biotechs with RNA-targeting platforms (e.g., Silence Therapeutics, Arrowhead). Its primary differentiation is its integrated AI/ML-driven discovery engine (OligoCreator®), which it positions for superior speed and precision in candidate design compared to more traditional methods.